ReviewJournal of molecular histology2004
Tumour biological aspects of CD24, a mucin-like adhesion molecule.
Review in Journal of molecular histology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 149 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
149 citing papers in PubMed, 2 syntheses or guidelines pooled it, 308 citations in OpenAlex.
- Pooled it
- Clinicopathological and prognostic significance of CD24 overexpression in patients with gastric cancer: a meta-analysis.PloS one · 2014Pooled it
- Prognosis of stage II colon cancer by non-neoplastic mucosa gene expression profiling.Oncogene · 2007Trial
- Review
- Antibody-dependent cellular phagocytosis in cancer immunotherapy: research and perspectives.Journal of translational medicine · 2026Review
- Mitoxantrone alters CD24/Siglec-10 expression in malignant brain tumor models.Scientific reports · 2026Article
- Salivary biomarkers in oral cancer diagnosis: advancing conventional treatment strategies.Military Medical Research · 2026Review
- Clonorchis sinensis-driven hepatocarcinogenesis via E2F1-CD24 transcriptional axis: mechanistic and therapeutic implications.Parasites & vectors · 2025Article
- CD24a knockout results in an enhanced macrophage- and CD8⁺ T cell-mediated anti-tumor immune responses in tumor microenvironment in a murine triple-negative breast cancer model.Journal of biomedical science · 2025Article
- Chemical and Enzymatic Synthesis of DisialylGb5 and Other Sialosides for Glycan Array Assembly and Evaluation of Siglec-Mediated Immune Checkpoint Inhibition.Molecules (Basel, Switzerland) · 2025Article
- Cancer metastasis: molecular mechanisms and therapeutic interventions.Molecular biomedicine · 2025Review
- Transcriptome Reveals Molecular Mechanisms of Neuroendocrine Regulation of Allometric Growth in the Red Swamp Crayfish Procambarus clarkii.Marine biotechnology (New York, N.Y.) · 2024Article
- Siglec-G Suppresses CD8Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- CD24 affects the immunosuppressive effect of tumor-infiltrating cells and tumor resistance in a variety of cancers.Discover oncology · 2024Article
- Network analysis to identify driver genes and combination drugs in brain cancer.Scientific reports · 2024Article
- LINC00525 enhances ZNF460-regulated CD24 expression through the sponge miR-125a-5p to promote malignant progression of breast cancer.Journal of cancer research and clinical oncology · 2024Article
- Comparative Analysis of Primary Ovarian Cancer Cells and Established Cell Lines as a New Tool for Studies on Ovarian Cancer Cell Complexity.International journal of molecular sciences · 2024Article
- The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma In Vivo Models Confers a Major Survival Advantage in a CD24-dependent Manner.Cancer research communications · 2024Article
- Harnessing microRNA-enriched extracellular vesicles for liquid biopsy.Frontiers in molecular biosciences · 2024Review
- From mechanism to therapy: the journey of CD24 in cancer.Frontiers in immunology · 2024Review
89 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD24 is a molecule that recently has raised considerable attention in tumour biology. It is involved in cell adhesion and metastatic tumour spread. It has also been described as a new diagnostic marker of tumours, of neuroendocrine differentiation and, possibly most intriguing of all, of patient prognosis. High rates of CD24 expression detected by immunohistochemistry have been found in epithelial ovarian cancer (83%), breast cancer (85%), non-small cell lung cancer (45%), prostate cancer (48%) and pancreatic cancer (72%). With the exception of pancreatic cancer, high rates of CD24 are significantly associated with a more aggressive course of the disease, a finding that remains significant in a multivariate analysis. The aim of this review is to summarize relevant work covering these aspects of CD24.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.